Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Summary

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 3 parts: Part A is a single ascending dose (SAD) study in healthy subjects, Part B is a multiple ascending dose (MAD) study in subjects with stable, mild asthma, and Part C (Biomarker) is a multiple dose study in subjects with stable, moderate-to-severe asthma.

Timeline

Start

2018-11-07

Primary completion

2020-07-13

Completion

2020-07-13

Outcome

Met primary endpoint

release “We met our primary objectives with the Phase 1 Part C study in moderate-to-severe asthmatics dosing TD-8236 with an inhaled corticosteroid.” theravance.com ↗

Drugs

Indications